Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
about
Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionRamucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinomaClinical utility of ramucirumab in advanced gastric cancerCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyReceptor tyrosine kinase-mediated angiogenesisGastric Cancer: New Drugs - New StrategiesEvolution of ramucirumab in the treatment of cancer - A review of literatureA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyPerspectives on utilizing unique features of microfluidics technology for particle and cell sorting.Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide.Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.Identification of the insulin-like growth factor II receptor as a novel receptor for binding and invasion by Listeria monocytogenes.Generation of high-affinity chicken single-chain Fv antibody fragments for measurement of the Pseudonitzschia pungens toxin domoic acidOptimizing the affinity and specificity of proteins with molecular display.Design of synthetic antibody libraries.Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.Engineering of stable bispecific antibodies targeting IL-17A and IL-23.Identification of peptide ligands for targeting to the blood-brain barrierSelection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.The VEGF family in cancer and antibody-based strategies for their inhibition.Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.An altered camelid-like single domain anti-idiotypic antibody fragment of HM-1 killer toxin: acts as an effective antifungal agent.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in micePhage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Molecular targeting to treat gastric cancer.Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design.A novel rabbit immunospot array assay on a chip allows for the rapid generation of rabbit monoclonal antibodies with high affinityRamucirumab: successfully targeting angiogenesis in gastric cancer.Anti-angiogenic therapies for advanced esophago-gastric cancerEngineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.Generation of a single chain antibody variable fragment (scFv) to sense selectively RhoB activation.Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.Radioimmunotherapy with engineered antibodies.Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
P2860
Q26738860-B852A1D5-0D5A-4147-A046-F8364967941CQ26777690-2228546E-B0C2-4325-A688-E938F6CB94CDQ26785665-275A2096-6EB8-47F6-AF93-DAB42098A87DQ26801289-B49FCD9F-D25F-46AE-B8E4-8037F688F7C8Q26824462-FAD1ECE8-F2D3-4FE7-949B-52DE15A40597Q27001612-1541E0EC-C08D-4DB1-8922-6BBB9D9BA5C8Q27028079-1025E13D-E522-4242-8653-28F1428E2F38Q28276412-9FC61479-B4F4-4B56-8FD8-153A6C78F867Q28749085-0A9FBCFB-DAD3-4A78-AE0E-5545CDDA830BQ30358961-4E407DF0-F2A1-4C93-B18F-1FBF12BD16D5Q30455612-A4F97848-066E-4D50-B6E7-C5EA265E3041Q30478456-8CDB251A-C1FA-48EC-B7BA-4AC121AB7A1BQ31007381-87262B8E-19AB-4B7B-8DDD-D43C9CDF1860Q31016741-2F7A571C-7A7F-437A-A7D1-8359D27C6A4AQ33230045-047A172D-C81A-460E-8FF7-DD6A7BB2F046Q33242145-DA0322E3-737B-4E7B-BB5C-2B7FFE829286Q33252425-7F33CD43-7C16-402D-8A56-48BE5B7A3181Q33283622-4EA49138-C026-403E-9A34-4FE9D2188978Q33418595-0DF32C8C-A75F-4149-ABCE-275F0C8109EBQ33519833-787B6599-20AB-48D6-91D3-5CD1F0BAE1D2Q33531847-CF7FABA6-DC7C-4D67-A826-12262CB9FA56Q33566182-7D583052-BCCF-4EE4-8295-25208102DFE0Q33710574-80B5F5DD-DC5D-46C5-BCEE-30B7DC8132ECQ33733437-FD11FF4B-BFC9-4C9E-AF6E-65B4B7A792F0Q33793562-2C0A1B05-5176-44A5-A786-8A1D5B3DCF61Q33816063-1F6BF91C-B5D9-4D7B-9BC0-AF95234608C7Q34040956-7F3D7F1A-C5A2-4113-831E-AD0B611CD7B9Q34245416-9E6AA932-8A4E-44D1-A26E-38C2FAE0C29EQ34273411-1A534CB9-341C-4F11-B447-BC9603EF4EC5Q34326593-B0B48EF0-5A72-4520-9981-C692AECE0E92Q34419541-A247C4D9-E787-4443-BC63-764CC5AE11A1Q34540651-4E9A9DE3-7C11-4B6D-9866-0CB8BCB69262Q34616558-A757D2A1-8E52-4FE0-AE34-8C6ECA53CBB3Q34686222-595F28A5-64C8-49D7-A9A4-71FCFF7A8656Q34787415-87093581-DADC-40EC-9E3D-B5E802BA3895Q35388015-2D405D48-869C-4976-94E3-D3CFD87B69F3Q35525772-0C92AC3C-6558-499F-8847-1DC6B0A8C523Q35681517-7240E131-8693-4A27-B02A-3A3FE286CF40Q36132447-7DFDC056-7BA3-4D39-B34F-D34C068E930BQ36478734-D43024F8-3698-4884-AB7A-C868DD1A9F95
P2860
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@ast
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@en
type
label
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@ast
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@en
prefLabel
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@ast
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@en
P2093
P356
P1476
Tailoring in vitro selection f ...... nhanced neutralizing activity.
@en
P2093
Haifan Zhang
Juqun Shen
Larry Witte
Marie D Vil
Peter Bohlen
Xenia Jimenez
Zhenping Zhu
P304
43496-43507
P356
10.1074/JBC.M307742200
P407
P577
2003-08-12T00:00:00Z